Archives of Pediatric Infectious Diseases

Published by: Kowsar

Visceral Leishmaniasis: An Update and Literature Review

Abdollah Karimi 1 , Abdolvahab Alborzi 2 and Ali Amanati 2 , *
Authors Information
1 Pediatric Infections Research Center, Mofid Children’s Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2 Professor Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
Article information
  • Archives of Pediatric Infectious Diseases: July 01, 2016, 4 (3); e31612
  • Published Online: June 7, 2016
  • Article Type: Review Article
  • Received: July 17, 2015
  • Revised: September 2, 2015
  • Accepted: November 24, 2015
  • DOI: 10.5812/pedinfect.31612

To Cite: Karimi A, Alborzi A, Amanati A. Visceral Leishmaniasis: An Update and Literature Review, Arch Pediatr Infect Dis. 2016 ; 4(3):e31612. doi: 10.5812/pedinfect.31612.

Copyright © 2016, Pediartric Infections Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
  • 1. Jeronimo SMB, Sousa ADQ, Pearson RD. Leishmaniasis, in Tropical infectious diseases: principles, pathogens and practice. Elsevier Health Sci. 2011; : 696
  • 2. Carrillo E, Moreno J, Cruz I. What is responsible for a large and unusual outbreak of leishmaniasis in Madrid? Trends Parasitol. 2013; 29(12): 579-80[DOI][PubMed]
  • 3. Boelaert M, Sundar S. Leishmaniasis, in Manson's Tropical Diseases: Expert Consult-Online. 2013;
  • 4. World Health Organization . Who Report on Global Surveillance of Epidemic-Prone Infectious Diseases. 2000;
  • 5. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis. 2004; 27(5): 305-18[DOI][PubMed]
  • 6. Tabatabaei SM, Zahraei M, Ahmadnia H, Ghotbi M, Rahimi F. Principles of disease prevention and surveillance. 2006; : 249-50
  • 7. Alan JM. Leishmania Species: Visceral (Kala-Azar), Cutaneous, and Mucosal Leishmaniasis Mandell, Douglas, Bennett, Principles and practice of infectious diseases. 2015; : 3091
  • 8. Daumerie D, Savioli L, Crompton DWT, Peters P. Working to Overcome the Global Impact of Neglected Tropical Diseases: First WHO Report on Neglected Tropical Diseases. 2010;
  • 9. Monge-Maillo B, Norman FF, Cruz I, Alvar J, Lopez-Velez R. Visceral leishmaniasis and HIV coinfection in the Mediterranean region. PLoS Negl Trop Dis. 2014; 8(8): 3021[DOI][PubMed]
  • 10. Singh S. Changing trends in the epidemiology, clinical presentation, and diagnosis of Leishmania-HIV co-infection in India. Int J Infect Dis. 2014; 29: 103-12[DOI][PubMed]
  • 11. Shafiei R, Mohebali M, Akhoundi B, Galian MS, Kalantar F, Ashkan S, et al. Emergence of co-infection of visceral leishmaniasis in HIV-positive patients in northeast Iran: a preliminary study. Travel Med Infect Dis. 2014; 12(2): 173-8[DOI][PubMed]
  • 12. Mansueto P, Seidita A, Vitale G, Cascio A. Leishmaniasis in travelers: a literature review. Travel Med Infect Dis. 2014; 12(6 Pt A): 563-81[DOI][PubMed]
  • 13. Alborzi A, Rasouli M, Shamsizadeh A. Leishmania tropica-isolated patient with visceral leishmaniasis in southern Iran. Am J Trop Med Hyg. 2006; 74(2): 306-7[PubMed]
  • 14. Alborzi A, Pouladfar GR, Fakhar M, Motazedian MH, Hatam GR, Kadivar MR. Isolation of Leishmania tropica from a patient with visceral leishmaniasis and disseminated cutaneous leishmaniasis, southern Iran. Am J Trop Med Hyg. 2008; 79(3): 435-7[PubMed]
  • 15. Khoshdel A, Alborzi A, Rosouli M, Taheri E, Kiany S, Javadian MH. Increased levels of IL-10, IL-12, and IFN- in patients with visceral leishmaniasis. Braz J Infect Dis. 2009; 13(1): 44-6[PubMed]
  • 16. Peter C, Melby GMA. Immune responses to protozoans, in Clinical immunology: principles and practice. 2008;
  • 17. Cooper NR. Complement evasion strategies of microorganisms. Immunol Today. 1991; 12(9): 327-31[DOI][PubMed]
  • 18. Alborzi A, Torab Jahromi F. Autoantibodies and complement levels of kala-azar patients in the south of Iran. Irn J Med Sci. 1993; 18(3&4): 94-8
  • 19. Lynne SG. Leishmaniasis Textbook of pediatric infectious diseases. 2014;
  • 20. Russo R, Laguna F, Lopez-Velez R, Medrano FJ, Rosenthal E, Cacopardo B, et al. Visceral leishmaniasis in those infected with HIV: clinical aspects and other opportunistic infections. Ann Trop Med Parasitol. 2003; 97 Suppl 1: 99-105[DOI][PubMed]
  • 21. Dieter AS. Human Domiciles, in Exposure: A Guide to Sources of Infection. 2006; : 220
  • 22. Desjeux P. The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg. 2001; 95(3): 239-43
  • 23. World Health Organization . Control of the leishmaniases, technical report series. 2010;
  • 24. World Health Organization . WHO report on global surveillance of epidemic-prone infectious diseases, Chapter 10: Leishmaniasis and Leishmania/HIV co-infection. 2000;
  • 25. Alborzi A MN, Pourabbas B. Vertical transmission of Leishmania infantum from asymptomatic mother to the child. 5th Iranian Congress on Infectious Diseases and Tropical Medicine. 2008;
  • 26. Alborzi A, Pouladfar GR, Aelami MH. Visceral leishmaniasis; literature review and Iranian experience. ARCHCID. 2007; 2(2)
  • 27. Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling RW, et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol. 2007; 5(11): 873-82[DOI][PubMed]
  • 28. Davies CR, Mazloumi Gavgani AS. Age, acquired immunity and the risk of visceral leishmaniasis: a prospective study in Iran. Parasitology. 1999; 119 ( Pt 3): 247-57[PubMed]
  • 29. Nateghian A. Clinical findings and initial treatment response of patients with visceral Leishmaniasis admitted in Ali asghar children hospital from 1976 to 2010 in Tehran, Iran. ARCHCID. 2012; 6(3): 108-11
  • 30. Karimi A, Jahromy MH. Visceral Leishmaniasis: The disease, in Visceral Leishmaniasis In Iran and World. 2008;
  • 31. Zijlstra EE, El-Hassan AM. Leishmaniasis in Sudan. 3. Visceral leishmaniasis. Trans R Soc Trop Med Hyg. 2001; 95: 27-58
  • 32. Karimi A, Amanati A, Ghanaie RM, Mohajerzadeh L. Co-infection of Leishmania and Tuberculosis. ARCHCID. 2014; 2(1): 183-7
  • 33. Kadivar MR, Kajbaf TZ, Karimi A, Alborzi A. Childhood visceral leishmaniasis complicated by bacterial infections. East Mediterr Health J. 2000; 6(5-6): 879-83[PubMed]
  • 34. Marshall BG, Kropf P, Murray K, Clark C, Flanagan AM, Davidson RN, et al. Bronchopulmonary and mediastinal leishmaniasis: an unusual clinical presentation of Leishmania donovani infection. Clin Infect Dis. 2000; 30(5): 764-9[DOI][PubMed]
  • 35. Antinori S, Cascio A, Parravicini C, Bianchi R, Corbellino M. Leishmaniasis among organ transplant recipients. Lancet Infect Dis. 2008; 8(3): 191-9[DOI][PubMed]
  • 36. van Griensven J, Carrillo E, Lopez-Velez R, Lynen L, Moreno J. Leishmaniasis in immunosuppressed individuals. Clin Microbiol Infect. 2014; 20(4): 286-99[DOI][PubMed]
  • 37. Karimi A, Jahromy MH. Review article of Kala azar In Iran, in Visceral Leishmaniasis In Iran and World. 2008; : 112
  • 38. Vannan KV. Diagnosis of Pulmonary Parasitic Diseases Parasitic Diseases of the Lungs. 2013; : 3
  • 39. da Silva MR, Stewart JM, Costa CH. Sensitivity of bone marrow aspirates in the diagnosis of visceral leishmaniasis. Am J Trop Med Hyg. 2005; 72(6): 811-4[PubMed]
  • 40. National Vector Borne Disease Control Programme . Kala-azar, Guidelines on Diagnosis and Treatment. 2014;
  • 41. Martinez P, de la Vega E, Laguna F, Soriano V, Puente S, Moreno V, et al. Diagnosis of visceral leishmaniasis in HIV-infected individuals using peripheral blood smears. AIDS. 1993; 7(2): 227-30[PubMed]
  • 42. Salam MA, Khan MG, Bhaskar KR, Afrad MH, Huda MM, Mondal D. Peripheral blood buffy coat smear: a promising tool for diagnosis of visceral leishmaniasis. J Clin Microbiol. 2012; 50(3): 837-40[DOI][PubMed]
  • 43. Alborzi A, Rasouli M, Nademi Z, Kadivar MR, Pourabbas B. Evaluation of rK39 strip test for the diagnosis of visceral leishmaniasis in infants. East Mediterr Health J. 2006; 12(3-4): 294-9[PubMed]
  • 44. Alborzi A, Pourabbas B, Shahian F, Mardaneh J, Pouladfar GR, Ziyaeyan M. Detection of Leishmania infantum kinetoplast DNA in the whole blood of asymptomatic individuals by PCR-ELISA and comparison with other infection markers in endemic areas, southern Iran. Am J Trop Med Hyg. 2008; 79(6): 839-42[PubMed]
  • 45. Pourabbas B, Ghadimi Moghadam A, Pouladfar G, Rezaee Z, Alborzi A. Quantification of Leishmania infantum kinetoplast DNA for monitoring the response to meglumine antimoniate therapy in visceral leishmaniasis. Am J Trop Med Hyg. 2013; 88(5): 868-71[DOI][PubMed]
  • 46. Kumar P, Pai K, Tripathi K, Pandey HP, Sundar S. Immunoblot analysis of the humoral immune response to Leishmania donovani polypeptides in cases of human visceral leishmaniasis: its usefulness in prognosis. Clin Diagn Lab Immunol. 2002; 9(5): 1119-23
  • 47. Culha G, Akyar I, Yildiz Zeyrek F, Kurt O, Gunduz C, Ozensoy Toz S, et al. Leishmaniasis in Turkey: Determination of Leishmania Species by Matrix-Assisted Laser Desorption Ionization Time-Of-Flight Mass Spectrometry (MALDI-TOF MS). Iran J Parasitol. 2014; 9(2): 239-48[PubMed]
  • 48. Lopez-Velez R, Perez-Molina JA, Guerrero A, Baquero F, Villarrubia J, Escribano L, et al. Clinicoepidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain. Am J Trop Med Hyg. 1998; 58(4): 436-43[PubMed]
  • 49. Mira JA, Corzo JE, Rivero A, Macias J, De Leon FL, Torre-Cisneros J, et al. Frequency of visceral leishmaniasis relapses in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. Am J Trop Med Hyg. 2004; 70(3): 298-301[PubMed]
  • 50. Drugs for Neglected Diseases initiative. New treatments for HIV/VL co-infection for Africa. 2015;
  • 51. Karimi A, Alborzi A, Mahmoodi MR, Rakhshani AH, Kadivar MR. Short course anti-Leishmania therapy in children with visceral leishmaniasis. Iran J Med Sci. 1998; 23
  • 52. Andrew S, Douglas J. Miltefosine, Kucers' The Use of Antibiotics Sixth Edition: A Clinical Review of Antibacterial, Antifungal and Antiviral Drugs. 2010; : 2215
  • 53. Rijal S, Ostyn B, Uranw S, Rai K, Bhattarai NR, Dorlo TP, et al. Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. Clin Infect Dis. 2013; 56(11): 1530-8[DOI][PubMed]
  • 54. Sundar S, Singh A, Rai M, Prajapati VK, Singh AK, Ostyn B, et al. Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin Infect Dis. 2012; 55(4): 543-50[DOI][PubMed]
  • 55. Mohapatra S. Drug resistance in leishmaniasis: Newer developments. Trop Parasitol. 2014; 4(1): 4-9[DOI][PubMed]
  • 56. Ritmeijer K, Dejenie A, Assefa Y, Hundie TB, Mesure J, Boots G, et al. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis. 2006; 43(3): 357-64[DOI][PubMed]
  • 57. Goswami RP, Basu A, Rahman M. The role of secondary prophylaxis in the management of HIV-VL co-infection: 7 years experience from West Bengal. 2015;
  • 58. Manjunath PP, J SB. Tables of Anti-infective Agent Pharmacology Mandell, Douglas, Bennett's Principles and practice of infectious diseases. 2015; : 687
  • 59. Vanaerschot M, Dumetz F, Roy S, Ponte-Sucre A, Arevalo J, Dujardin JC. Treatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype? Expert Rev Anti Infect Ther. 2014; 12(8): 937-46[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments